Paradigm BioCapital Select Fund LP

No prior EDGAR filings from this manager indicate this is either a first-time raise or a manager new to SEC filing requirements, meaning allocators cannot benchmark this GP's fund economics, fee history, or operational track record against a prior vintage—this is a de novo entry into regulated hedge fund space.

Filing in May 2026 aligns with biotech and life-sciences capital deployment cycles, where Q2 fundraising typically targets deployment windows in late 2026 and 2027; however, biotech hedge funds face headwinds from volatile public biotech indices and compressed returns in the sector, making the timing contrarian rather than opportunistic.

Before engagement, verify whether Asefaw has prior investment or operational history in biotech outside EDGAR filings (prior hedge fund roles, portfolio company positions, or clinical/scientific background), as the absence of manager track record combined with a sector-specific fund name requires independent validation of sector expertise and deal access.